Wockhardt Files Fast-Acting Insulin Aspart Injection (ASPARAPID™) with DCGI, Strengthens Commitment to Diabetes Management
Wockhardt, a global pharmaceutical and biotechnology major, has filed its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This move reflects Wockhardt’s ongoing commitment to address the growing diabetes epidemic both in India and globally. The company's ASPARAPID™ is an indigenously developed product, underscoring its end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products. The market size of Aspart in India is currently estimated over INR 260 Cr. with only 2 players and is expected to grow significantly in the coming years. Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions.
Key Highlights
- Wockhardt files fast-acting insulin Aspart injection (ASPARAPID™) with DCGI, strengthening commitment to diabetes management.
- ASPARAPID™ is an indigenously developed product, showcasing Wockhardt’s end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products.
- ASPARAPID™ will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to patients for diabetes management.
- The market size of Aspart in India is currently estimated over INR 260 Cr. with only 2 players and is expected to grow significantly.
- Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions.